Prescription Pain Drugs Market Report

Prescription Pain Drugs Market - Global Professional Analysis and Forecast to 2026

  • POSTDATE：Nov 23, 2019
  • PAGES：143
  • REPORT CODE：GMM391139
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The worldwide Prescription Pain Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 11.9% during the forecast period.

    This report presents the market size and development trends by detailing the Prescription Pain Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Prescription Pain Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Prescription Pain Drugs industry and will help you to build a panoramic view of the industrial development.

    Prescription Pain Drugs Market, By Type:

    • Type 1

    • Type 2

    • Type 3

    Prescription Pain Drugs Market, By Application:

    • End-User 1

    • End-User 2

    • End-User 3

    Some of the leading players are as follows:

    • Elite Pharmaceuticals, Inc

    • Grunenthal GmbH.

    • Durect Corporation.

    • King Pharmaceuticals.

    • Zogenix, Inc

    • Insys Therapeutics Inc

    • Antibe Therapeutics Inc

    • Covidien plc

    • Bedrocan Cannabis Corp.

    • BioDelivery Sciences International, Inc

    • Pacira Pharmaceuticals Inc

    • GW Pharmaceuticals plc

    • Tweed Marijuana Inc.

    • NicOx SA

    • Trevena Inc.

    • Teva Pharmaceutical Industries Limited

    • Endo International plc

    • Marinus Pharmaceuticals Inc.

    • Pfizer Inc.

    • AcelRx Pharmaceuticals Inc

    • Purdue Pharma, LP

    • Indivior plc

    • Raptor Pharmaceutical Corp.

    • Collegium Pharmaceutical, Inc

    • Cara Therapeutics, Inc.

    • Acura Pharmaceuticals, Inc

    • Egalet Corp

    • Nektar Therapeutics

    • Allergan plc

    • Lannett Company, Inc.

    • Johnson & Johnson

    • Mayne Pharma Group Ltd.

    • Purdue Pharma, L.P.

    Geographically, Major regions are analyzed in details are as follows:

    • North America

    • Europe

    • Asia Pacific

    • Latin America

    • Middle East & Africa

  • Table of Contents

    1 Methodology and Scope

    • 1.1 Market Segmentation & Scope

      • 1.1.1 Technology Type

      • 1.1.2 Product

      • 1.1.3 Application

      • 1.1.4 Regional scope

      • 1.1.5 Estimates and forecast timeline

    • 1.2 Research Methodology

    • 1.3 Information Procurement

      • 1.3.1 Purchased database

      • 1.3.2 Internal database

      • 1.3.3 Secondary sources

      • 1.3.4 Primary research

      • 1.3.5 Details of primary research

    • 1.4 Information or Data Analysis

      • 1.4.1 Data analysis models

    • 1.5 Market Formulation & Validation

    • 1.6 Model Details

      • 1.6.1 Commodity flow analysis

      • 1.6.2 Volume price analysis

    • 1.7 List of Secondary Sources

    • 1.8 List of Abbreviations

    2 Executive Summary

    • 2.1 Market Outlook

    • 2.2 Segment Outlook

    3 Market Variables, Trends, & Scope

    • 3.1 Market Lineage Outlook

    • 3.1.1 Parent market outlook

      • 3.1.2 Ancillary market outlook

    • 3.2 Market Segmentation

      • 3.2.1 Analysis

    • 3.3 Market Dynamics

      • 3.3.1 Market driver analysis

      • 3.3.2 Market restraint analysis

      • 3.3.3 Industry opportunities

    • 3.4 Penetration & Growth Prospect Mapping

      • 3.4.1 Penetration & growth prospect mapping analysis

    • 3.5 Business Environment Analysis Tools

      • 3.5.1 Porter's five forces analysis

      • 3.5.2 PESTLE analysis

      • 3.5.3 Major deals & strategic alliances analysis

    4 Prescription Pain Drugs Market: Technology Type Analysis

    • 4.1 Prescription Pain Drugs Technology Type Market Share Analysis, 2018 & 2026

    • 4.2 Prescription Pain Drugs Technology Type Market: Segment Dashboard

    • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

      • 4.3.1 Type 1

      • 4.3.2 Type 2

      • 4.3.3 Type 3

    5 Prescription Pain Drugs Market: Product Analysis

    • 5.1 Prescription Pain Drugs Product Market Share Analysis, 2018 & 2026

    • 5.2 Prescription Pain Drugs Product Market: Segment Dashboard

    • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

    6 Prescription Pain Drugs Market: Application Analysis

    • 6.1 Prescription Pain Drugs Application Market Share Analysis, 2018 & 2026

    • 6.2 Prescription Pain Drugs Application Market: Segment Dashboard

    • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

      • 6.3.1 End-User 1

      • 6.3.2 End-User 1

      • 6.3.3 End-User 3

    7 Prescription Pain Drugs Market: Regional Analysis

    • 7.1 Prescription Pain Drugs Regional Market Share Analysis, 2018 & 2026

    • 7.2 Prescription Pain Drugs Regional Market: Segment Dashboard

    • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

    • 7.4 List of Players at Regional Level

      • 7.4.1 North America

      • 7.4.2 Europe

      • 7.4.3 Asia Pacific

    • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

      • 7.5.1 North America

      • 7.5.2 Europe

      • 7.5.3 Asia Pacific

      • 7.5.4 Latin America

      • 7.5.5 MEA

    • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

      • 7.6.1 North America

      • 7.6.2 Europe

      • 7.6.3 Asia Pacific

      • 7.6.4 Latin America

      • 7.6.5 Middle East & Africa

    8 Competitive Analysis

    • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

    • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

    • 8.3 Vendor Landscape

      • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

    9 Company Profiles

    • 9.1 Elite Pharmaceuticals, Inc

      • 9.1.1 Elite Pharmaceuticals, Inc Company overview

      • 9.1.2 Financial performance

      • 9.1.3 Product benchmarking

      • 9.1.4 Strategic initiatives

      • 9.1.5 SWOT analysis

    • 9.2 Grunenthal GmbH.

      • 9.2.1 Grunenthal GmbH. Company overview

      • 9.2.2 Financial performance

      • 9.2.3 Product benchmarking

      • 9.2.4 Strategic initiatives

      • 9.2.5 SWOT analysis

    • 9.3 Durect Corporation.

      • 9.3.1 Durect Corporation. Company overview

      • 9.3.2 Financial performance

      • 9.3.3 Product benchmarking

      • 9.3.4 Strategic initiatives

      • 9.3.5 SWOT analysis

    • 9.4 King Pharmaceuticals.

      • 9.4.1 King Pharmaceuticals. Company overview

      • 9.4.2 Financial performance

      • 9.4.3 Product benchmarking

      • 9.4.4 Strategic initiatives

      • 9.4.5 SWOT analysis

    • 9.5 Zogenix, Inc

      • 9.5.1 Zogenix, Inc Company overview

      • 9.5.2 Financial performance

      • 9.5.3 Product benchmarking

      • 9.5.4 Strategic initiatives

      • 9.5.5 SWOT analysis

    • 9.6 Insys Therapeutics Inc

      • 9.6.1 Insys Therapeutics Inc Company overview

      • 9.6.2 Financial performance

      • 9.6.3 Product benchmarking

      • 9.6.4 Strategic initiatives

      • 9.6.5 SWOT analysis

    • 9.7 Antibe Therapeutics Inc

      • 9.7.1 Antibe Therapeutics Inc Company overview

      • 9.7.2 Financial performance

      • 9.7.3 Product benchmarking

      • 9.7.4 Strategic initiatives

      • 9.7.5 SWOT analysis

    • 9.8 Covidien plc

      • 9.8.1 Covidien plc Company overview

      • 9.8.2 Financial performance

      • 9.8.3 Product benchmarking

      • 9.8.4 Strategic initiatives

      • 9.8.5 SWOT analysis

    • 9.9 Bedrocan Cannabis Corp.

      • 9.9.1 Bedrocan Cannabis Corp. Company overview

      • 9.9.2 Financial performance

      • 9.9.3 Product benchmarking

      • 9.9.4 Strategic initiatives

      • 9.9.5 SWOT analysis

    • 9.10 BioDelivery Sciences International, Inc

      • 9.10.1 BioDelivery Sciences International, Inc Company overview

      • 9.10.2 Financial performance

      • 9.10.3 Product benchmarking

      • 9.10.4 Strategic initiatives

      • 9.10.5 SWOT analysis

    • 9.11 Pacira Pharmaceuticals Inc

      • 9.11.1 Pacira Pharmaceuticals Inc Company overview

      • 9.11.2 Financial performance

      • 9.11.3 Product benchmarking

      • 9.11.4 Strategic initiatives

      • 9.11.5 SWOT analysis

    • 9.12 GW Pharmaceuticals plc

      • 9.12.1 GW Pharmaceuticals plc Company overview

      • 9.12.2 Financial performance

      • 9.12.3 Product benchmarking

      • 9.12.4 Strategic initiatives

      • 9.12.5 SWOT analysis

    • 9.13 Tweed Marijuana Inc.

      • 9.13.1 Tweed Marijuana Inc. Company overview

      • 9.13.2 Financial performance

      • 9.13.3 Product benchmarking

      • 9.13.4 Strategic initiatives

      • 9.13.5 SWOT analysis

    • 9.14 NicOx SA

      • 9.14.1 NicOx SA Company overview

      • 9.14.2 Financial performance

      • 9.14.3 Product benchmarking

      • 9.14.4 Strategic initiatives

      • 9.14.5 SWOT analysis

    • 9.15 Trevena Inc.

      • 9.15.1 Trevena Inc. Company overview

      • 9.15.2 Financial performance

      • 9.15.3 Product benchmarking

      • 9.15.4 Strategic initiatives

      • 9.15.5 SWOT analysis

    • 9.16 Teva Pharmaceutical Industries Limited

      • 9.16.1 Teva Pharmaceutical Industries Limited Company overview

      • 9.16.2 Financial performance

      • 9.16.3 Product benchmarking

      • 9.16.4 Strategic initiatives

      • 9.16.5 SWOT analysis

    • 9.17 Endo International plc

      • 9.17.1 Endo International plc Company overview

      • 9.17.2 Financial performance

      • 9.17.3 Product benchmarking

      • 9.17.4 Strategic initiatives

      • 9.17.5 SWOT analysis

    • 9.18 Marinus Pharmaceuticals Inc.

      • 9.18.1 Marinus Pharmaceuticals Inc. Company overview

      • 9.18.2 Financial performance

      • 9.18.3 Product benchmarking

      • 9.18.4 Strategic initiatives

      • 9.18.5 SWOT analysis

    • 9.19 Pfizer Inc.

      • 9.19.1 Pfizer Inc. Company overview

      • 9.19.2 Financial performance

      • 9.19.3 Product benchmarking

      • 9.19.4 Strategic initiatives

      • 9.19.5 SWOT analysis

    • 9.20 AcelRx Pharmaceuticals Inc

      • 9.20.1 AcelRx Pharmaceuticals Inc Company overview

      • 9.20.2 Financial performance

      • 9.20.3 Product benchmarking

      • 9.20.4 Strategic initiatives

      • 9.20.5 SWOT analysis

    • 9.21 Purdue Pharma, LP

      • 9.21.1 Purdue Pharma, LP Company overview

      • 9.21.2 Financial performance

      • 9.21.3 Product benchmarking

      • 9.21.4 Strategic initiatives

      • 9.21.5 SWOT analysis

    • 9.22 Indivior plc

      • 9.22.1 Indivior plc Company overview

      • 9.22.2 Financial performance

      • 9.22.3 Product benchmarking

      • 9.22.4 Strategic initiatives

      • 9.22.5 SWOT analysis

    • 9.23 Raptor Pharmaceutical Corp.

      • 9.23.1 Raptor Pharmaceutical Corp. Company overview

      • 9.23.2 Financial performance

      • 9.23.3 Product benchmarking

      • 9.23.4 Strategic initiatives

      • 9.23.5 SWOT analysis

    • 9.24 Collegium Pharmaceutical, Inc

      • 9.24.1 Collegium Pharmaceutical, Inc Company overview

      • 9.24.2 Financial performance

      • 9.24.3 Product benchmarking

      • 9.24.4 Strategic initiatives

      • 9.24.5 SWOT analysis

    • 9.25 Cara Therapeutics, Inc.

      • 9.25.1 Cara Therapeutics, Inc. Company overview

      • 9.25.2 Financial performance

      • 9.25.3 Product benchmarking

      • 9.25.4 Strategic initiatives

      • 9.25.5 SWOT analysis

    • 9.26 Acura Pharmaceuticals, Inc

      • 9.26.1 Acura Pharmaceuticals, Inc Company overview

      • 9.26.2 Financial performance

      • 9.26.3 Product benchmarking

      • 9.26.4 Strategic initiatives

      • 9.26.5 SWOT analysis

    • 9.27 Egalet Corp

      • 9.27.1 Egalet Corp Company overview

      • 9.27.2 Financial performance

      • 9.27.3 Product benchmarking

      • 9.27.4 Strategic initiatives

      • 9.27.5 SWOT analysis

    • 9.28 Nektar Therapeutics

      • 9.28.1 Nektar Therapeutics Company overview

      • 9.28.2 Financial performance

      • 9.28.3 Product benchmarking

      • 9.28.4 Strategic initiatives

      • 9.28.5 SWOT analysis

    • 9.29 Allergan plc

      • 9.29.1 Allergan plc Company overview

      • 9.29.2 Financial performance

      • 9.29.3 Product benchmarking

      • 9.29.4 Strategic initiatives

      • 9.29.5 SWOT analysis

    • 9.30 Lannett Company, Inc.

      • 9.30.1 Lannett Company, Inc. Company overview

      • 9.30.2 Financial performance

      • 9.30.3 Product benchmarking

      • 9.30.4 Strategic initiatives

      • 9.30.5 SWOT analysis

    • 9.31 Johnson & Johnson

      • 9.31.1 Johnson & Johnson Company overview

      • 9.31.2 Financial performance

      • 9.31.3 Product benchmarking

      • 9.31.4 Strategic initiatives

      • 9.31.5 SWOT analysis

    • 9.32 Mayne Pharma Group Ltd.

      • 9.32.1 Mayne Pharma Group Ltd. Company overview

      • 9.32.2 Financial performance

      • 9.32.3 Product benchmarking

      • 9.32.4 Strategic initiatives

      • 9.32.5 SWOT analysis

    • 9.33 Purdue Pharma, L.P.

      • 9.33.1 Purdue Pharma, L.P. Company overview

      • 9.33.2 Financial performance

      • 9.33.3 Product benchmarking

      • 9.33.4 Strategic initiatives

      • 9.33.5 SWOT analysis

     

    The List of Tables and Figures (Totals 95 Figures and 159 Tables)

    • Figure Type 1 Prescription Pain Drugs market, 2015 - 2026 (USD Million)

    • Figure Type 2 Prescription Pain Drugs market, 2015 - 2026 (USD Million)

    • Figure Type 3 Prescription Pain Drugs market, 2015 - 2026 (USD Million)

    • Figure End-User 1 market, 2015 - 2026 (USD Million)

    • Figure End-User 2 market, 2015 - 2026 (USD Million)

    • Figure End-User 3 market, 2015 - 2026 (USD Million)

    • Table List of players in North America

    • Table List of players in Europe

    • Table List of players in Asia Pacific

    • Table SWOT analysis

    • Table North America Prescription Pain Drugs market, by country, 2015 - 2026 (USD Million)

    • Table North America Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table North America Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table North America Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.S. Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table U.S. Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table U.S. Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Canada Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Canada Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Canada Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Europe Prescription Pain Drugs market, by country, 2015 - 2026 (USD Million)

    • Table Europe Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Europe Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Europe Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.K. Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table U.K. Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table U.K. Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Germany Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Germany Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Germany Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table France Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table France Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table France Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Italy Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Italy Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Italy Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Spain Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Spain Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Spain Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Asia Pacific Prescription Pain Drugs market, by country, 2015 - 2026 (USD Million)

    • Table Asia Pacific Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Asia Pacific Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Asia Pacific Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table China Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table China Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table China Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Japan Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Japan Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Japan Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table India Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table India Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table India Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Latin America Prescription Pain Drugs market, by country, 2015 - 2026 (USD Million)

    • Table Latin America Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Latin America Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Latin America Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Brazil Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Brazil Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Brazil Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Mexico Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Mexico Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Mexico Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Argentina Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Argentina Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Argentina Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table MEA Prescription Pain Drugs market, by country, 2015 - 2026 (USD Million)

    • Table MEA Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table MEA Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table MEA Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table South Africa Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table South Africa Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table South Africa Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Nigeria Prescription Pain Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Nigeria Prescription Pain Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Nigeria Prescription Pain Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Company market position analysis

    • Table Company Profiles

    • Table Elite Pharmaceuticals, Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Grunenthal GmbH. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Durect Corporation. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table King Pharmaceuticals. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Zogenix, Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Insys Therapeutics Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Antibe Therapeutics Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Covidien plc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Bedrocan Cannabis Corp. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table BioDelivery Sciences International, Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Pacira Pharmaceuticals Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table GW Pharmaceuticals plc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Tweed Marijuana Inc. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table NicOx SA Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Trevena Inc. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Teva Pharmaceutical Industries Limited Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Endo International plc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Marinus Pharmaceuticals Inc. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Pfizer Inc. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table AcelRx Pharmaceuticals Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Purdue Pharma, LP Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Indivior plc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Raptor Pharmaceutical Corp. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Collegium Pharmaceutical, Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Cara Therapeutics, Inc. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Acura Pharmaceuticals, Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Egalet Corp Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Nektar Therapeutics Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Allergan plc Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Lannett Company, Inc. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Mayne Pharma Group Ltd. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Purdue Pharma, L.P. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US